A comparison of the attitudes about the legalization of marijuana use for medical purposes by cancer patients in two cancer centers located in a legalized and a non-legalized state.

Authors

null

Kimberson Cochien Tanco

Unit 1414, Houston, TX

Kimberson Cochien Tanco, Donato Dumlao, Rebecca Rae Kreis, Kristy Nguyen, Seyedeh Dibaj, Diane D. Liu, Vidyasagargoud Marupakula, Ayesha Shaikh, Janet L. Williams, Hilda P. Cantu, Marie Jones, Wendy Beers, Michael McMahon, Julio A. Allo, Brenda Noggy, Walter F. Baile, Eduardo Bruera

Organizations

Unit 1414, Houston, TX, Banner MD Anderson Cancer Center, Gilbert, AZ, Banner MD Anderson Cancer Center, Mesa, AZ, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

Other

Background: There is limited evidence on the perception of medical marijuana (MM) among cancer patients in a legalized vs. a non-legalized state. In this study, we compared the attitudes of cancer patients in a legalized (Arizona) vs. a non-legalized state (Texas) on legalizing marijuana for medical use and their perception of its medical usefulness. We also examined their preference of MM for pain, anxiety and depression against current treatments and examined any demographic, physical or psychosocial association with its perception. Methods: Two hundred adult cancer patients were enrolled from the outpatient palliative care centers at Banner MD Anderson Cancer Center in Gilbert, AZ and The University of Texas MD Anderson Cancer Center in Houston, TX. All patients were residents of the state where they were enrolled. Various physical and psychosocial instruments were collected including a survey designed to determine attitudes and beliefs of patient towards MM. Due to the sensitivity of information, no identifiers were associated with data recorded. Results: No significant difference was found between both locations in attitude towards legalizing MM [Arizona 92% (85 - 97%) vs. Texas 90% (82 - 95%); p = 0.81] and belief of its usefulness [Arizona 97% (92 - 99%) vs. Texas 93% (86 - 97%); p = 0.33]. Patients preferred MM over current treatments for anxiety [60% (51 – 68%); p = 0.003] but not for pain and depression. Patients who favored legalizing MM were younger (median age 59 vs. 67 y; p = 0.027) and had worse Edmonton Symptom Assessment System fatigue (median 5 vs 3; p = 0.015) and appetite (median 3 vs 0.5; p = 0.004) scores. There was a significant difference among those who have used MM (95%) and have not used MM (88%) in support of legalization of MM (p = 0.024). Conclusions: Cancer patients from both legalized and non-legalized states showed strong support for legalization of marijuana for medical purposes and strong belief in its medical use. Patient who are younger, and had worse fatigue and appetite showed higher support for medical marijuana.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Palliative and Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B: Advance Care Planning; Caregiver Support; Coordination and Continuity of Care; End-of-Life Care; Models of Care; Survivorship; and Symptom Biology, Assessment and Management

Track

Advance Care Planning,End-of-Life Care,Survivorship,Coordination and Continuity of Care,Symptom Biology, Assessment, and Management,Models of Care,Caregiver Support

Sub Track

Symptom Biology, Assessment, and Management

Citation

J Clin Oncol 36, 2018 (suppl 34; abstr 191)

DOI

10.1200/JCO.2018.36.34_suppl.191

Abstract #

191

Poster Bd #

E9

Abstract Disclosures

Similar Abstracts

First Author: Meghan Beck

First Author: Talya Salz

First Author: Desiree Rachel Azizoddin

Abstract

2019 Gastrointestinal Cancers Symposium

The need for improvement in the management of fatigue, depression and pain in pancreatic cancer.

First Author: Amy Westermann